258 related articles for article (PubMed ID: 26909131)
1. Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals.
Xu YP; Yang M
World J Gastrointest Oncol; 2016 Feb; 8(2):165-72. PubMed ID: 26909131
[TBL] [Abstract][Full Text] [Related]
2. Prospects in radionuclide imaging of prostate cancer.
Lütje S; Boerman OC; van Rij CM; Sedelaar M; Helfrich W; Oyen WJ; Mulders PF
Prostate; 2012 Aug; 72(11):1262-72. PubMed ID: 22127918
[TBL] [Abstract][Full Text] [Related]
3. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
4. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
5. Radiolabeled prostate-specific membrane antigen small-molecule inhibitors.
Will L; Sonni I; Kopka K; Kratochwil C; Giesel FL; Haberkorn U
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):168-180. PubMed ID: 28217987
[TBL] [Abstract][Full Text] [Related]
6. Cross-sectional imaging and the role of positron emission tomography in pancreatic cancer evaluation.
Raman SP; Chen Y; Fishman EK
Semin Oncol; 2015 Feb; 42(1):40-58. PubMed ID: 25726051
[TBL] [Abstract][Full Text] [Related]
7. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations.
Sendler A; Avril N; Helmberger H; Stollfuss J; Weber W; Bengel F; Schwaiger M; Roder JD; Siewert JR
World J Surg; 2000 Sep; 24(9):1121-9. PubMed ID: 11036292
[TBL] [Abstract][Full Text] [Related]
8. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
9. 18F-FLT PET imaging of cellular proliferation in pancreatic cancer.
Lamarca A; Asselin MC; Manoharan P; McNamara MG; Trigonis I; Hubner R; Saleem A; Valle JW
Crit Rev Oncol Hematol; 2016 Mar; 99():158-69. PubMed ID: 26778585
[TBL] [Abstract][Full Text] [Related]
10. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
11. [Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions].
Zimny M; Schumpelick V
Chirurg; 2001 Sep; 72(9):989-94. PubMed ID: 11594284
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
14. Update on positron emission tomography for imaging of prostate cancer.
Kitajima K; Murphy RC; Nathan MA; Sugimura K
Int J Urol; 2014 Jan; 21(1):12-23. PubMed ID: 23991644
[TBL] [Abstract][Full Text] [Related]
15. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled inorganic nanoparticles for positron emission tomography imaging of cancer: an overview.
Chakravarty R; Goel S; Dash A; Cai W
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):181-204. PubMed ID: 28124549
[TBL] [Abstract][Full Text] [Related]
17. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD
Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and staging of pancreatic cancer by positron emission tomography.
Berberat P; Friess H; Kashiwagi M; Beger HG; Büchler MW
World J Surg; 1999 Sep; 23(9):882-7. PubMed ID: 10449814
[TBL] [Abstract][Full Text] [Related]
19. Molecular imaging (PET) of brain tumors.
Basu S; Alavi A
Neuroimaging Clin N Am; 2009 Nov; 19(4):625-46. PubMed ID: 19959009
[TBL] [Abstract][Full Text] [Related]
20. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]